



MEDIA RELEASE

CMAX, IDT AUSTRALIA OPENS NEW CLINICAL TRIALS FACILITY IN ADELAIDE

Leading generic drug manufacturer IDT Australia is pleased to announce the successful opening of Australia's largest cutting edge clinical trials facility, CMAX Adelaide.

IDT's CMAX facility is now Australia's most contemporary, dedicated early-phase clinical trial facility, providing a foundation for leading medical science organisations to deliver world-leading research.

The central Adelaide facility was opened last Friday, 29 April, by IDT Australia Chairman Mr Graeme Kaufman together with The Hon. Katrine Hildyard MP Assistant Minister to the Premier and Member for Reynell who was representing the Hon. Jack Snelling MP, Minister for Health Industries.

Projects that will be undertaken in the new facility include a second study investigating an innovative wristwatch like device which aims to provide an early warning system for hypoglycemic events in diabetic patients and a gene therapy study developed by a Japanese biopharmaceutical company for the treatment of peripheral arterial disease.

This collaborative gene therapy study will be overseen by Professor Stephen Nicholls of SAHMRI, and involve expertise of clinicians from The Queen Elizabeth Hospital and Royal Adelaide Hospital. Study participants will be brought to CMAX for many of the procedures to take advantage of the clinic's capabilities.

South Australia's Minister for Health Industries, the Hon Jack Snelling, said that each Phase 1 trial at CMAX will inject revenue into the local economy, sometimes as much as \$1 million, and involve over 50 staff, including 30 nurses and 15 lab technicians.

"Adelaide is also an important site for Phase 2 and Phase 3 trials, making the city a one- stop-shop for pharmaceutical companies. The South Australian Government is targeting health industry investment, an important part of this is attracting clinical trials from the United States, Europe and China." Minister Snelling said.

CMAX trials have resulted in the advancement of medicines, used in a wide range of health care treatments from cancer treatment and pain control to skin conditions and hormone replacement therapies.

"Our specialist teams strive to ensure the very best outcomes for patients and clients whilst conducting leading research with the world's top pharmaceutical companies. We hold ourselves to the highest standards, working with our government and industry partners to benefit the health outcomes of communities world-wide," Mr Kaufman said.

Ms Jane Kelly, Vice President Clinical Service CMAX spoke of the team's excitement in relocating to be adjacent to one of the largest health focused city precincts in the southern hemisphere, Adelaide's BioMed City.



“In the two decades that I’ve been working with CMAX, our trials have assisted in improving the quality of life for hundreds-of-thousands of people. Our volunteer database has grown, as has the volume of returning volunteers. Our partners, clients and our volunteers are integral to the success of important medicine development and we thank them for their ongoing support.

“We are all excited about the start of a new era. We look forward to working with our valued clients and partners on developing innovative health care solutions that will provide life enhancing benefits to loved ones and all communities,” she said.

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. IDT is commercializing a portfolio of 24 generic drugs to manufacture and sell via US distribution partners. The company is also exploring EU and Japanese sales opportunities. With IDT’s 2013 temozolomide ANDA filing this signifies IDT’s move to rapidly become a specialty generics business with near term revenue build up.

IDT has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based at the Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.